A study that used intravenous immunoglobulin (IVIG) to treat severe intractable AD in children reported that ICAM was significantly reduced after the IVIG treatment and that the determination of ICAM-1 levels may be useful for monitoring the disease activity of AD in childhood (122). This evidence concerns the gene ICAM1 and Alzheimer disease.